Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Escitalopram beneficial against neuroticism

02 Nov 2019

Treatment with the selective serotonin reuptake inhibitor escitalopram may confer beneficial effects on neuroticism, possibly by inducing reduction in anxiety, a recent study has shown.

Researchers reanalysed data from a randomized placebo‐controlled trial that failed to find an effect of escitalopram on neuroticism and state anxiety in a nonclinical sample to examine the drug’s unique effects on two neuroticism factors, trait anxiety and mood instability.

The study population included 80 adults free of psychiatric disorders but who had a first‐degree relative with major depression. These adults were randomized to receive escitalopram 10 mg/day or placebo for 4 weeks.

A greater reduction in the Eysenck Personality Questionnaire (EPQ) trait anxiety was observed in the escitalopram group, whereas EPQ mood instability decreased more in the placebo group, although neither difference was statistically significant.

Of note, participants in the escitalopram vs placebo group showed a greater decline in the Hamilton Anxiety Rating Scale (HAM‐A) scores, but the difference was only borderline statistically significant (p=0.09).

There was a significant interaction between baseline EPQ neuroticism and treatment condition (p=0.004), such that the effect of escitalopram on HAM‐A scores was statistically significant in participants with higher levels of EPQ trait anxiety, even after controlling for baseline HAM‐A scores.

According to the researchers, the present data could be used to guide future research on the effects of antidepressants in nonclinical populations. They underscored the need to replicate the findings in a properly designed study, given the posthoc and exploratory nature of the current analysis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.